Lakefront Biotherapeutics (LKFT) Return on Capital Employed (2016 - 2026)
Lakefront Biotherapeutics (LKFT) reported Return on Capital Employed of 11.62% for Q1 2026, up 1666.0% year-over-year from 0.66% in Q1 2025, and up 26.7% quarter-over-quarter from 9.17% in Q4 2025.
Lakefront Biotherapeutics (LKFT) Return on Capital Employed (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 11 years of Return on Capital Employed data on file, last reported at 11.62% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 11.62%, up 1666.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 11.62% (up 1666.0% YoY), and the FY2025 annual result was 8.56%, up 1335.0% from the prior year.
- Return on Capital Employed climbed to 11.62% in Q1 2026 per LKFT's latest filing, from 9.17% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 11.62% in Q1 2026 and troughed at 11.92% in Q3 2025.
- A 5-year average of 0.3% and a median of 1.61% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed sank 893 bps in 2025, then jumped 1666 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 2.63% in 2022, then soared by 265 bps to 4.34% in 2023, then tumbled by 135 bps to 1.53% in 2024, then soared by 698 bps to 9.17% in 2025, then grew by 27 bps to 11.62% in 2026.
- Business Quant data shows LKFT's Return on Capital Employed at 11.62% in Q1 2026, 9.17% in Q4 2025, and 11.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -107.40% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -50.43% |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | 11.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.62% |
| Dec 31, 2025 | 9.17% |
| Sep 30, 2025 | -11.92% |
| Jun 30, 2025 | -3.29% |
| Mar 31, 2025 | -5.03% |
| Dec 31, 2024 | -1.53% |
| Mar 31, 2024 | 3.90% |
| Dec 31, 2023 | 4.34% |
| Mar 31, 2023 | -1.68% |
| Mar 31, 2022 | -2.63% |
| Dec 31, 2021 | -5.83% |
| Jun 30, 2020 | 6.34% |
| Mar 31, 2020 | 6.99% |
| Dec 31, 2019 | 6.83% |
| Sep 30, 2019 | 13.36% |
| Jun 30, 2019 | -6.59% |
| Mar 31, 2019 | -5.69% |
| Dec 31, 2018 | -4.04% |
| Sep 30, 2018 | -17.66% |
| Jun 30, 2018 | 0.05% |